Pancreatic Cancer Research

ResearcherJohns Hopkins UniversityActive in the last 2 years

Alexander S. Rosemurgy

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-6882-911X; OpenAlex author ID A5066603550, A5113206413. Sources: ClinicalTrials.gov.

Their work

Papers
14 (first author 1, last author 9)
Trials
2 (principal investigator on 1)
Grants
0
Labs led
2
Collaborators
39
Papers, trials and grants by year

2001: 1 trial · 2002: none · 2003: none · 2004: none · 2005: none · 2006: none · 2007: none · 2008: none · 2009: none · 2010: none · 2011: 1 paper · 2012: 3 papers · 2013: 2 papers, 1 trial · 2014: none · 2015: 1 paper · 2016: 1 paper · 2017: 4 papers · 2018: none · 2019: none · 2020: none · 2021: none · 2022: none · 2023: none · 2024: 2 papers

Papers 14

  1. Treatment of locally advanced pancreatic cancer using localized trans-arterial micro perfusion of gemcitabine: combined analysis of RR1 and RR2. First author DOI 10.1093/oncolo/oyae178↗
  2. The Oncological Stress Test of Neoadjuvant Therapy: A Systematic Review in Outcomes of Neoadjuvant Therapy Compared to Upfront Resection Approach for Borderlin… Last author DOI 10.1177/00031348241248703↗
  3. Has survival improved following resection for pancreatic adenocarcinoma? Last author DOI 10.1016/j.amjsurg.2017.05.007↗
  4. Safety Study of Targeted and Localized Intra-Arterial Delivery of Gemcitabine in Patients with Locally Advanced Pancreatic Adenocarcinoma. Co-author DOI 10.1089/pancan.2017.0011↗
  5. Phase 2 placebo-controlled, double-blind trial of dasatinib added to gemcitabine for patients with locally-advanced pancreatic cancer. Co-author DOI 10.1093/annonc/mdw607↗
  6. Sulfonylureas (not metformin) improve survival of patients with diabetes and resectable pancreatic adenocarcinoma. Last author DOI 10.1097/ij9.0000000000000015↗
  7. Can pancreatic cancer behavior be predicted based on computed tomography measurements of fat and muscle mass? Last author DOI 10.1097/ij9.0000000000000004↗
  8. Increasing body mass index portends abbreviated survival following pancreatoduodenectomy for pancreatic adenocarcinoma. Last author DOI 10.1016/j.amjsurg.2014.12.037↗
  9. Nontherapeutic celiotomy incidence is not affected by volume of pancreaticoduodenectomy for pancreatic adenocarcinoma. Last author DOI 10.1177/000313481307900818↗
  10. Randomized phase III multi-institutional study of TNFerade biologic with fluorouracil and radiotherapy for locally advanced pancreatic cancer: final results. Co-author DOI 10.1200/jco.2012.44.7516↗
  11. Pancreatic adenocarcinoma: complete tumor extirpation improves survival benefit despite larger tumors for patients who undergo distal pancreatectomy and splene… Last author DOI 10.1007/s11605-011-1765-6↗
  12. Survival after pancreatectomy for pancreatic adenocarcinoma is not impacted by performance status. Last author DOI 10.1016/j.amjsurg.2012.01.016↗
  13. EUS or percutaneously guided intratumoral TNFerade biologic with 5-fluorouracil and radiotherapy for first-line treatment of locally advanced pancreatic cancer… Co-author DOI 10.1016/j.gie.2011.10.007↗
  14. Preoperative computed tomography measurements of pancreatic steatosis and visceral fat: prognostic markers for dissemination and lethality of pancreatic adenoc… Last author DOI 10.1111/j.1477-2574.2011.00304.x↗

Trials 2

  1. Pancreas Volume and Diabetes Status Following Pancreatectomy Principal investigator NCT02823678↗
  2. Fluorouracil, External-Beam Radiation Therapy, and Gemcitabine With or Without Brachytherapy Using Phosphorus P32 in Treating Patients With Locally or Regional… Study chair NCT00079365↗

Closest collaborators

The 25 strongest of 39 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Sharona B Ross · 7 shared papers, 2012–2024 · strength 0.66
  2. Kenneth Luberice · 6 shared papers, 2012–2017 · strength 0.38
  3. Ramtin Agah · 2 shared papers, 2017–2024 · strength 0.26
  4. Iswanto Sucandy · 1 shared paper, 2024 · strength 0.26
  5. Paul G. Toomey · 4 shared papers, 2012–2017 · strength 0.19
  6. Hassan A. Hatoum · 1 shared paper, 2024 · strength 0.18
  7. Peter Muscarella · 1 shared paper, 2024 · strength 0.18
  8. Barish H. Edil · 1 shared paper, 2024 · strength 0.18
  9. Emmanuel E. Zervos · 1 shared paper, 2024 · strength 0.18
  10. Jonathan Matthew Hernandez · 3 shared papers, 2011–2012 · strength 0.10
  11. Abhishek Mathur · 2 shared papers, 2011–2015 · strength 0.09
  12. Whalen Clark · 1 shared paper, 2016 · strength 0.07
  13. Peter James O'Dwyer · 1 shared paper, 2017 · strength 0.06
  14. G. Deplanque · 1 shared paper, 2017 · strength 0.06
  15. Thomas R. Jeffry Evans · 1 shared paper, 2017 · strength 0.06
  16. Denis Pezet · 1 shared paper, 2017 · strength 0.06
  17. Bohuslav Melichar · 1 shared paper, 2017 · strength 0.06
  18. Gyorgy Bodoky · 1 shared paper, 2017 · strength 0.06
  19. Eric Van Cutsem · 1 shared paper, 2017 · strength 0.06
  20. Marcia Irene Canto · 2 shared papers, 2012–2013 · strength 0.05
  21. John E. Mullinax · 1 shared paper, 2012 · strength 0.03
  22. Phuoc Tho Tran · 1 shared paper, 2013 · strength 0.03
  23. Aaron Tyler Wild · 1 shared paper, 2013 · strength 0.03
  24. Joseph M. Herman · 1 shared paper, 2013 · strength 0.03
  25. Ross C. Donehower · 1 shared paper, 2013 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.